Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a diabetes drug tame blood sugar swings after bariatric surgery?

NCT ID NCT07515391

Disease control Sponsor: Dasman Diabetes Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether dapagliflozin, a diabetes drug, can reduce dangerous blood sugar highs and lows in people who have had bariatric surgery. The study will enroll 30 participants, both with and without type 2 diabetes, and monitor glucose levels continuously for 12 weeks. The goal is to see if the drug improves overall glucose control and reduces hypoglycemia and hyperglycemia episodes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dapagliflozin (a diabetes drug that helps the kidneys remove extra sugar through urine)
What this could lead to
If it works, this could show that dapagliflozin helps stabilize blood sugar levels after bariatric surgery, potentially improving diabetes management.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply to everyone. The drug also carries risks like dehydration or urinary infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2019

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. People diagnosed with type 2 diabetes prior to bariatric surgery. 2. People did not have diabetes prior to bariatric surgery. 3. Willing to participate in this study. Exclusion Criteria: 1. Type 1 diabetes 2. Secondary diabetes 3. History of ketoacidosis 4. History of pancreatitis and pancreatectomy. 5. History of primary renal glycosuria or hereditary glucose-galactose malabsorption. 6. Active diabetes complications, nephropathy (dipstick positive proteinuria, or reduced eGFR (\<60 ml/min), proliferative retinopathy. 7. Clinically significant abnormal liver function test. 8. Pregnant ladies, or intending pregnancy or breastfeeding. 9. Patients using insulin therapy or a sulfonylurea. 10. Uncontrolled hypertension. 11. Uncontrolled thyroid disease. 12. Any history of serious hypertension reaction to the dapagliflozin or SGLT-2 inhibitor. 13. History of malignancy within 5-year of screening. 14. Presence of any other medical condition that would in the opinion of the investigator, preclude safe participation in the study. 15. HbA1c \>10.5 16. Unable to sign the consent form.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bariatric surgery candidate are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bariatric surgery candidate TYPE2 diabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dasman Diabetes Institute

    Kuwait City, Dasman, 15462, Kuwait

More trials for these conditions

Other studies related to the condition(s) this trial covers.